These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8923856)

  • 21. Changes of thyroid function during long-term hGH therapy in GHD children. A possible relationship with catch-up growth?
    Seminara S; Stagi S; Candura L; Scrivano M; Lenzi L; Nanni L; Pagliai F; Chiarelli F
    Horm Metab Res; 2005 Dec; 37(12):751-6. PubMed ID: 16372229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Delemarre-van de Waal HA; Vulsma T; Wit JM; Rouwé CW; Reeser HM; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
    Cotterill AM; McKenna WJ; Brady AF; Sharland M; Elsawi M; Yamada M; Camacho-Hübner C; Kelnar CJ; Dunger DB; Patton MA; Savage MO
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth enhancement by dopaminergic therapy in children with intrauterine growth retardation.
    Huseman CA
    J Clin Endocrinol Metab; 1985 Sep; 61(3):514-9. PubMed ID: 3926809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular defects in achondroplasia and the effects of growth hormone treatment.
    Seino Y; Moriwake T; Tanaka H; Inoue M; Kanzaki S; Tanaka T; Matsuo N; Niimi H
    Acta Paediatr Suppl; 1999 Feb; 88(428):118-20. PubMed ID: 10102070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].
    Mancilla EE; Poggi H; Repetto G; García C; Foradori A; Cattani A
    Rev Med Chil; 2003 Dec; 131(12):1405-10. PubMed ID: 15022403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone (GH) treatment in short normal children: absence of influence of time of injection and resistance to GH autofeedback.
    Chanoine JP; Vanderschueren-Lodeweyckx M; Maes M; Thiry-Counson G; Craen M; Van Vliet G
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1269-75. PubMed ID: 1955508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The correlation of the IGF-I, IGFBP-3, and ALS generation test to height velocity after 6 months of recombinant growth hormone therapy in girls with Turner syndrome.
    Collett-Solberg PF; Pessoa de Queiroz AN; Cardoso ME; Jusan RC; Vaisman M; Guimarães MM
    Growth Horm IGF Res; 2006 Aug; 16(4):240-6. PubMed ID: 16908209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the response of growth hormone-deficient children to long term treatment with human growth hormone.
    Rudman D; Kutner MH; Goldsmith MA; Blackston RD
    J Clin Endocrinol Metab; 1979 Mar; 48(3):472-7. PubMed ID: 218997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
    Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
    Olney RC; Prickett TC; Espiner EA; Mackenzie WG; Duker AL; Ditro C; Zabel B; Hasegawa T; Kitoh H; Aylsworth AS; Bober MB
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E355-9. PubMed ID: 25387261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of growth hormone therapy for patients with skeletal dysplasia.
    Kanazawa H; Tanaka H; Inoue M; Yamanaka Y; Namba N; Seino Y
    J Bone Miner Metab; 2003; 21(5):307-10. PubMed ID: 12928832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosynthetic human growth hormone: current status and future questions.
    Thompson RG; Conforti P; Holcombe J
    J Endocrinol Invest; 1989; 12(8 Suppl 3):35-9. PubMed ID: 2809097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.
    Sas TC; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Hoorweg-Nijman JJ; Vulsma T; Massa GG; Rouwe CW; Reeser HM; Gerver WJ; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4607-12. PubMed ID: 10599727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Near normalization of adult height and body proportions by growth hormone in pycnodysostosis.
    Rothenbühler A; Piquard C; Gueorguieva I; Lahlou N; Linglart A; Bougnères P
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2827-31. PubMed ID: 20357177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of one year therapy with recombinant human growth hormone (rhGH) on growth velocity, calcium-phosphorus metabolism, bone mineral density and changes in body composition in children with growth hormone deficiency (GHD)].
    Zak T; Basiak A; Zubkiewicz-Kucharska A; Noczyńska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(1):39-43. PubMed ID: 20529605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prediction of body height and shortening of the lower part of the body in adults with achondroplasia].
    Marík I; Zemková D; Kubát R; Rygl M; Friedlová J
    Acta Chir Orthop Traumatol Cech; 1989 Dec; 56(6):507-15. PubMed ID: 2633593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.